Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

The use of developmental therapeutics has expanded the treatment of gynecologic cancers beyond traditional chemotherapy. Since options can now be biomarker-driven, sequencing of agents is key to ...

Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug ...

In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...